Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Background Information:
INCB018424 (Ruxolitinib) is a potent, selective and orally bioavailable inhibitor of JAK1 (Ki 2.7 nM) and JAK2 (Ki 4.5 nM). Inhibit JAK3 at Ki 343 nM. Over 100 fold selectivity against a broad panel of other kinases.
Reference:
1. R. A. Mesa, Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs, 2010, 13(6), 394-403.
2. C Campas-Moya. Ruxolitinib. Drugs Fut. 2010, 35(6), 457.
APIM050174: INCB018424 (RUXOLITINIB)
CAS No.: 941678-49-5.
Molecular Formula: C17H18N6 ? 0.2H2O.
Molecular Weight: 310.
Purity: Refer to Certificate of Analysis, batch-specific.
QC: HPLC, 1HNMR, Chiral HPLC, and Quantitative Elemental Analysis.
Solubility: Water, >50 mM.
Storage: Store at 0°C (short term), -20°C (long term), desiccated.
Copyright © 2009-2022 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.